1-7 of 7
Tristan M. Sissung
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

Free
Jing Wu, Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung, Yu-Ting Su, Ying Pang, Guangyang Yu, Madison K. Butler, Tito R. Mendoza, Elizabeth Vera, Salman Ahmad, Christine Bryla, Matthew Lindsley, Ewa Grajkowska, Kelly Mentges, Lisa Boris, Ramya Antony, Nancy Garren, Christine Siegel, Nicole Lollo, Christine Cordova, Orwa Aboud, Brett J. Theeler, Eric M. Burton, Marta Penas-Prado, Heather Leeper, Javier Gonzales, Terri S. Armstrong, Katherine R. Calvo, William D. Figg, Douglas B. Kuhns, John I. Gallin, Mark R. Gilbert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3298–3306.
https://doi.org/10.1158/1078-0432.CCR-20-4730
Published: 15 June 2021
View articletitled, Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Open the PDF for Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas in another window
Includes: Multimedia, Supplementary data
Journal Articles

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Free
Jung-Min Lee, Cody J. Peer, Minshu Yu, Lauren Amable, Nicolas Gordon, Christina M. Annunziata, Nicole Houston, Andrew K.L. Goey, Tristan M. Sissung, Bernard Parker, Lori Minasian, Victoria L. Chiou, Robert F. Murphy, Brigitte C. Widemann, William D. Figg, Elise C. Kohn
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (6): 1397–1406.
https://doi.org/10.1158/1078-0432.CCR-16-1546
Published: 14 March 2017
View articletitled, Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Open the PDF for Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer in another window
Includes: Supplementary data
Journal Articles

Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

Free
Anne M. Noonan, Robin A. Eisch, David J. Liewehr, Tristan M. Sissung, David J. Venzon, Thomas P. Flagg, Mark C. Haigney, Seth M. Steinberg, William D. Figg, Richard L. Piekarz, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 3095–3104.
https://doi.org/10.1158/1078-0432.CCR-13-0109
Published: 30 May 2013
View articletitled, Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
Open the PDF for Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel in another window
Includes: Supplementary data
Journal Articles

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Free
Cody J. Peer, Tristan M. Sissung, AeRang Kim, Lokesh Jain, Sukyung Woo, Erin R. Gardner, C. Tyler Kirkland, Sarah M. Troutman, Bevin C. English, Emily D. Richardson, Joel Federspiel, David Venzon, William Dahut, Elise Kohn, Shivaani Kummar, Robert Yarchoan, Giuseppe Giaccone, Brigitte Widemann, William D. Figg
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 2099–2107.
https://doi.org/10.1158/1078-0432.CCR-11-2484
Published: 01 April 2012
View articletitled, Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Open the PDF for Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia in another window
Includes: Supplementary data
Journal Articles

Impact of ABCB1 Allelic Variants on QTc Interval Prolongation

Free
Tristan M. Sissung, Erin R. Gardner, Richard L. Piekarz, Reuben Howden, Xiaohong Chen, Sukyung Woo, Ryan Franke, James A. Clark, Laura Miller-DeGraff, Seth M. Steinberg, David Venzon, David Liewehr, Steven R. Kleeberger, Susan E. Bates, Douglas K. Price, Douglas R. Rosing, Christopher Cabell, Alex Sparreboom, William D. Figg
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 937–946.
https://doi.org/10.1158/1078-0432.CCR-10-0925
Published: 15 February 2011
View articletitled, Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
Open the PDF for Impact of ABCB1 Allelic Variants on QTc Interval Prolongation in another window
Includes: Supplementary data
Journal Articles

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

Free
Sukyung Woo, Erin R. Gardner, Xiaohong Chen, Sandra B. Ockers, Caitlin E. Baum, Tristan M. Sissung, Douglas K. Price, Robin Frye, Richard L. Piekarz, Susan E. Bates, William D. Figg
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1496–1503.
https://doi.org/10.1158/1078-0432.CCR-08-1215
Published: 19 February 2009
View articletitled, Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
Open the PDF for Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma in another window
Journal Articles

ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

Free
Tristan M. Sissung, Caitlin E. Baum, John Deeken, Douglas K. Price, Jeanny Aragon-Ching, Seth M. Steinberg, William Dahut, Alex Sparreboom, William D. Figg
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4543–4549.
https://doi.org/10.1158/1078-0432.CCR-07-4230
Published: 15 July 2008
View articletitled, ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel
Open the PDF for ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel in another window